Dr. Reddy's Labs launches bortezomib injection in US market

Dr. Reddy’s Laboratories Ltd announced the launch of bortezomib for injection 3.5 mg/vial, approved by the US Food and Drug Administration (FDA) via a 505(b)(2) new drug application (NDA) pathway for intravenous use only. Dr. Reddy’s bortezomib for injection 3.5 mg/vial is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “We are pleased to bring this product to market for the customers and patients who will benefit from this cost efficient alternative in the market place,” explains Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the US market as we continue to augment our portfolio of products in the Hospital segment.”

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.002703 seconds